2024 Revenues ($USD) : $6.66B

UCB, the Brussels-based biopharma focusing on neurology and immunology, put up some strong numbers in 2024. Revenue jumped a significant 17% (+19% at constant exchange rates) to hit €6.15 billion.

Robust sales from its newly launched growth drivers were core growth drivers – products like BIMZELX, EVENITY, and FINTEPLA saw their combined net sales triple to over €1.3 billion. Of course, solid contributions from established drugs like CIMZIA and BRIVIACT helped too. Profitability also climbed, with adjusted EBITDA up 9% (+18% constant currency) to €1.48 billion, translating to a 24% margin. Core EPS landed at €4.98.

The company noted it reached over 3.1 million patients through its efforts in its core therapeutic areas. UCB also bagged some important regulatory approvals in 2024, notably getting BIMZELX the green light in China and the U.S. across several immunological indications.

Looking ahead to 2025, UCB is projecting continued growth, forecasting revenue between €6.5-€6.7 billion and aiming for an adjusted EBITDA margin of 30%. This signals confidence in its growth path and operational efficiency efforts.

Analysts seem to view UCB's 2024 as pretty impressive, seeing it as validation of the company's strategy. The successful rollout of new growth drivers is key, helping lessen the reliance on older products. While the 2025 guidance looks positive, crucial factors will be continued market uptake of these newer therapies, successful pipeline execution (with updates expected on nine potential medicines), and hitting those margin targets despite competitive headwinds.